Sandoz Sued Over Schizophrenia Drug Patent

Law360, New York (March 5, 2007, 12:00 AM EST) -- A Japanese pharmaceutical company has filed a patent infringement suit against the generics arm of Novartis AG in response to the subsidiary’s bid to obtain U.S. regulatory approval for a generic version of schizophrenia and bipolar disorder treatment Abilify.

Tokyo-based Otsuka Pharmaceutical Co. Ltd. filed the lawsuit Friday in New Jersey against Sandoz Inc., seeking to bar Sandoz’ proposed generics from entering the U.S. market until the expiration of an Otsuka patent.

At issue is U.S. Patent Number 5,006,528, entitled “carbostyril derivatives,” which was issued and...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.